📰On The Record – 8th July 2026

Microsoft began swapping OpenAI and Anthropic's models for its own homegrown MAI system in parts of Excel and Outlook, according to Bloomberg, with the in-house tech already fielding tens of thousands of prompts a week. Officially, nothing's changed — OpenAI and Anthropic remain "key partners." Unofficially, this is Microsoft doing what every smart landlord eventually does: building its own version of the thing it's been renting. It matters because the AI boom has always run on a simple assumption — that the model-makers hold the power. Microsoft just quietly reminded everyone who actually owns the building.

Four US states are seeking roughly $1.4 trillion in penalties from Meta, accusing it of designing Facebook and Instagram to hook young users while downplaying the harm. That number isn't just eye-watering — it's close to Meta's entire market value, which tells you these states aren't negotiating, they're making a statement. Meta's calling it legally and factually baseless, and an August trial looms. Whatever the final number turns out to be, this case is a preview of how expensive "we didn't know" is about to get for every platform built on teenage attention.

Union Pacific and Norfolk Southern went before US regulators to defend their $85 billion merger, promising $3.5 billion in annual shipper savings and offering to sell off some jointly owned assets to ease competition worries. Rivals and freight customers aren't buying it, warning fewer competitors usually means higher prices. If approved, it'd create America's first true coast-to-coast railroad — a genuinely big deal for anyone who ships anything, anywhere.

SpaceX joined the Nasdaq-100 just weeks after its blockbuster IPO, triggering an expected $4 billion in automatic buying from index-tracking funds. Morgan Stanley, Goldman Sachs and JPMorgan are all bullish, betting on Starlink and reusable rockets. A few analysts quietly note the roughly $2 trillion valuation already assumes a lot goes right.

Vertex Pharmaceuticals agreed to buy Crinetics for $10 billion in cash, a 102% premium, pushing beyond cystic fibrosis into rare hormonal disorders. The deal hands Vertex an approved acromegaly drug and a promising late-stage pipeline. It's the latest sign that Big Pharma would rather buy innovation than wait around to build it.

John Lewis is closing its in-store currency exchange and gift-wrapping desks, putting around 200 jobs at risk as shopping habits keep shifting online. Affected staff will get support and possible redeployment. It's a small line in a much bigger story: even a brand this beloved can't out-nostalgia the internet forever.

A daily score of business conditions (scored out of 100), with a breakdown of what’s driving it.

The Daily Business Index dipped to 49.8 today, down 4.2 points, as two stories collided: oil prices jumped more than 5% after Washington revoked Iran's licence to sell crude and tensions rose around the Strait of Hormuz, while a chip-sector selloff that started in Seoul and Tokyo spread to Wall Street, pulling US stocks back from record highs. Together, they're a reminder that even a booming market can carry hidden fragilities — worth watching if you're exposed to energy costs or tech-heavy portfolios in the days ahead.

SpaceX isn't a scrappy garage startup anymore, but it's still behaving like one — moving fast, raising eyebrows, and making everyone else look slow. Its Nasdaq-100 entry, weeks after a blockbuster IPO, means billions in automatic investment from funds that simply track the index. The bigger story here is Starlink and reusable rockets turning space into infrastructure rather than spectacle, with AI workloads now added to the pitch. Even sceptics admit the ambition is real. The valuation is the only thing anyone's arguing about.

Global hiring is changing fast. From AI's impact on HR to evolving compliance requirements and international expansion strategies, the rules are constantly shifting.

Oyster's events bring together HR leaders, founders, operators, and global employment experts to discuss what's working now—and what's coming next.

Whether you're hiring internationally today or planning for tomorrow, you'll walk away with practical insights you can actually use.

Explore Hiring Events

On 8th July 2025, President Trump threatened a 200% tariff on pharmaceutical imports, part of the same trade offensive that saw a 50% copper tariff announced that same day. It never landed anywhere near 200%, but it rattled drugmakers and supply chains for months. A year on, with Vertex dropping $10 billion on a rare-disease deal, it's a reminder that Big Pharma's biggest headaches these days come from Washington as often as from the lab.

What it means: When a company joins a major index like the Nasdaq-100, funds that simply track that index are required to buy its shares automatically — no opinion, no analysis, just mechanical buying. It's why SpaceX's index entry alone is expected to trigger roughly $4 billion in buying, regardless of what anyone actually thinks the stock is worth.